|
US4217344A
(en)
|
1976-06-23 |
1980-08-12 |
L'oreal |
Compositions containing aqueous dispersions of lipid spheres
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4186183A
(en)
|
1978-03-29 |
1980-01-29 |
The United States Of America As Represented By The Secretary Of The Army |
Liposome carriers in chemotherapy of leishmaniasis
|
|
US4261975A
(en)
|
1979-09-19 |
1981-04-14 |
Merck & Co., Inc. |
Viral liposome particle
|
|
US4485054A
(en)
|
1982-10-04 |
1984-11-27 |
Lipoderm Pharmaceuticals Limited |
Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US5049386A
(en)
|
1985-01-07 |
1991-09-17 |
Syntex (U.S.A.) Inc. |
N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4946787A
(en)
|
1985-01-07 |
1990-08-07 |
Syntex (U.S.A.) Inc. |
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4774085A
(en)
|
1985-07-09 |
1988-09-27 |
501 Board of Regents, Univ. of Texas |
Pharmaceutical administration systems containing a mixture of immunomodulators
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
AU7979491A
(en)
|
1990-05-03 |
1991-11-27 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
AU6704794A
(en)
|
1993-04-13 |
1994-11-08 |
Sloan-Kettering Institute For Cancer Research |
Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
|
|
CA2186118C
(en)
|
1994-03-23 |
2010-10-19 |
Richard W. Hanson |
Compacted nucleic acids and their delivery to cells
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US6010613A
(en)
|
1995-12-08 |
2000-01-04 |
Cyto Pulse Sciences, Inc. |
Method of treating materials with pulsed electrical fields
|
|
US6642043B1
(en)
|
1996-03-12 |
2003-11-04 |
Sloan-Kettering Institute For Cancer Research |
Double mutants of dihydrofolate reductase and methods of using same
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US20060206949A1
(en)
|
2003-01-28 |
2006-09-14 |
Sylvain Arnould |
Custom-made meganuclease and use thereof
|
|
CN1826408B
(zh)
|
2003-03-14 |
2011-01-26 |
塞托·帕尔斯科技公司 |
大容量离体电穿孔法
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
SG10201806573TA
(en)
*
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
AU2013312838B2
(en)
|
2012-09-04 |
2018-11-29 |
Cellectis |
Multi-chain chimeric antigen receptor and uses thereof
|
|
WO2014055442A2
(en)
*
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
CA2912375C
(en)
|
2013-05-13 |
2023-03-14 |
Cellectis |
Methods for engineering highly active t cell for immunotherapy
|
|
JP6608807B2
(ja)
|
2013-05-29 |
2019-11-20 |
セレクティス |
Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
|
|
JP6976058B2
(ja)
|
2013-11-22 |
2021-12-01 |
セレクティスCellectis |
免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
|
|
ES2918501T3
(es)
*
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
JP6665102B2
(ja)
*
|
2014-02-21 |
2020-03-13 |
セレクティスＣｅｌｌｅｃｔｉｓ |
制御性ｔ細胞をインサイチューで阻害するための方法
|
|
RU2752933C2
(ru)
|
2014-03-11 |
2021-08-11 |
Селлектис |
Способ создания т-клеток, пригодных для аллогенной трансплантации
|
|
WO2016142532A1
(en)
*
|
2015-03-11 |
2016-09-15 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
WO2016172583A1
(en)
*
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11466291B2
(en)
*
|
2016-07-06 |
2022-10-11 |
Cellectis |
Sequential gene editing in primary immune cells
|
|
IL265953B2
(en)
*
|
2016-10-19 |
2026-05-01 |
Cellectis Sa |
Gene insertion designed to target for enhanced immune cell therapy
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
AU2018292181B2
(en)
*
|
2017-06-30 |
2025-04-10 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
CA3069557A1
(en)
*
|
2017-07-21 |
2019-01-24 |
Cellectis |
Engineered immune cells resistant to tumor microoenvironment
|
|
JP7621795B2
(ja)
*
|
2017-10-19 |
2025-01-27 |
セレクティス |
改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み
|
|
CN107723275B
(zh)
*
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
CN110526991A
(zh)
*
|
2018-05-25 |
2019-12-03 |
深圳宾德生物技术有限公司 |
靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
|
|
PE20210642A1
(es)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores de pd-1/pd-l1
|
|
JP2022510218A
(ja)
|
2018-11-30 |
2022-01-26 |
メモリアル スローン ケタリング キャンサー センター |
ヘテロ二量体四価特異性抗体およびこれらの使用
|
|
BR112022005423A2
(pt)
*
|
2019-09-23 |
2022-06-21 |
Univ Pennsylvania |
Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap)
|
|
WO2021120526A1
(zh)
*
|
2019-12-16 |
2021-06-24 |
四川大学华西医院 |
同时靶向间皮素和fap的双靶点嵌合抗原受体及其用途
|
|
WO2021257808A2
(en)
*
|
2020-06-17 |
2021-12-23 |
Proviva Therapeutics (Hong Kong) Limited |
Antibodies to fibroblast activation protein and b7h3
|